Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31107192 | 1.00 | SMYD2 (0.44) | SMYD2SMN1; SMN2CYP3A4HTTACHE | |
| SCHEMBL26172223 | 1.00 | SMYD2 (0.44) | SMYD2SMN1; SMN2CYP3A4HTTACHE | |
| SCHEMBL31058599 | 0.79 | SMYD2 (0.43) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL31058601 | 0.78 | SMYD2 (0.43) | SMYD2SMN1; SMN2CYP3A4HTTCA12 | |
| SCHEMBL31252098 | 0.78 | SMYD2 (0.41) | SMYD2SMN1; SMN2CYP3A4HTTACHE | |
| SCHEMBL29624597 | 0.76 | SMYD2 (0.43) | SMYD2SMN1; SMN2CYP3A4HTTCA12 | |
| SCHEMBL22470033 | 0.75 | SMYD2 (0.44) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL21744771 | 0.75 | CYP1A2 (0.40) | ACHECYP1A2CYP2C9CYP2C19CA12 | |
| SCHEMBL12324775 | 0.75 | CHRM2 (0.46) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL4743617 | 0.74 | CYP1A2 (0.53) | ACHECYP1A2CYP2C9CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077051-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB3, ERBB2 | SMYD2 3591/4885SMN1; SMN2 3990/4885CYP3A4 3237/4885 |
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | SMYD2 2579/4885SMN1; SMN2 4558/4885CYP3A4 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.